» Articles » PMID: 11092283

The Diabetes Prevention Program: Baseline Characteristics of the Randomized Cohort. The Diabetes Prevention Program Research Group

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2000 Nov 25
PMID 11092283
Citations 143
Affiliations
Soon will be listed here.
Abstract

Objective: The Diabetes Prevention Program (DPP) is a 27-center randomized clinical trial designed to evaluate the safety and efficacy of interventions that may delay or prevent development of diabetes in people at increased risk for type 2 diabetes.

Research Design And Methods: Eligibility requirements were age > or = 25 years, BMI > or = 24 kg/m2 (> or = 22 kg/m2 for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 5.3-6.9 mmol/l (or < or = 6.9 mmol for American Indians). Randomization of participants into the DPP over 2.7 years ended in June 1999. Baseline data for the three treatment groups--intensive lifestyle modification, standard care plus metformin, and standard care plus placebo--are presented for the 3,234 participants who have been randomized.

Results: Of all participants, 55% were Caucasian, 20% were African-American, 16% were Hispanic, 5% were American Indian, and 4% were Asian-American. Their average age at entry was 51 +/- 10.7 years (mean +/- SD), and 67.7% were women. Moreover, 16% were < 40 years of age, and 20% were > or = 60 years of age. Of the women, 48% were postmenopausal. Men and women had similar frequencies of history of hypercholesterolemia (37 and 33%, respectively) or hypertension (29 and 26%, respectively). On the basis of fasting lipid determinations, 54% of men and 40% of women fit National Cholesterol Education Program criteria for abnormal lipid profiles. More men than women were current or former cigarette smokers or had a history of coronary heart disease. Furthermore, 66% of men and 71% of women had a first-degree relative with diabetes. Overall, BMI averaged 34.0 +/- 6.7 kg/m2 at baseline with 57% of the men and 73% of women having a BMI > or = 30 kg/m2. Average fasting plasma glucose (6.0 +/- 0.5 mmol/l) and HbA1c (5.9 +/- 0.5%) in men were comparable with values in women (5.9 +/- 0.4 mmol/l and 5.9 +/- 0.5%, respectively).

Conclusions: The DPP has successfully randomized a large cohort of participants with a wide distribution of age, obesity, and ethnic and racial backgrounds who are at high risk for developing type 2 diabetes. The study will examine the effects of interventions on the development of diabetes.

Citing Articles

Factors associated with diabetes mellitus and hypertension among adults in the northern rural area, Afghanistan.

Fayaz S, Hamajima N, Frozanfar M, Hamrah M, Inthaphatha S, Nishino K Nagoya J Med Sci. 2025; 86(4):564-577.

PMID: 39780927 PMC: 11704768. DOI: 10.18999/nagjms.86.4.564.


Long-term impact of Diabetes Prevention Program interventions on walking endurance.

Munshi M, Venditti E, Tjaden A, Knowler W, Boyko E, Middelbeek R Front Public Health. 2025; 12():1470035.

PMID: 39744353 PMC: 11688401. DOI: 10.3389/fpubh.2024.1470035.


The sleep for health study: A randomized clinical trial of the impact of insomnia treatment on glycemia in people with prediabetes.

LeBlanc E, Smith N, Hwang D, Young D, Oshiro C, Mayhew M Contemp Clin Trials. 2024; 149:107796.

PMID: 39730078 PMC: 11788072. DOI: 10.1016/j.cct.2024.107796.


The Group-basEd Telehealth behavioral WEight Loss Program Among Breast Cancer Survivors: A Pilot and Feasibility Study.

Allison K, McCuen-Wurst C, Raevsky A, Holmes N, Goldbach M, Guerra C Obes Sci Pract. 2024; 10(6):e70023.

PMID: 39713088 PMC: 11662970. DOI: 10.1002/osp4.70023.


Perceptions, facilitators, and barriers of participation for a behavioral weight loss group-based telehealth program for breast cancer survivors: a qualitative study.

Liu Y, De Jesus E, Goldbach M, Krouse R, Guerra C, Rendle K Support Care Cancer. 2024; 32(12):808.

PMID: 39567374 PMC: 11579159. DOI: 10.1007/s00520-024-08999-x.


References
1.
Lachin J . Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000; 21(3):167-89. DOI: 10.1016/s0197-2456(00)00046-5. View

2.
Saad M, Knowler W, Pettitt D, Nelson R, Mott D, BENNETT P . The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med. 1988; 319(23):1500-6. DOI: 10.1056/NEJM198812083192302. View

3.
Peterson J, Young D . Evaluation of the hexokinase-glucose-6-phosphate dehydrogenase method of determination of glucose in urine. Anal Biochem. 1968; 23(2):301-16. DOI: 10.1016/0003-2697(68)90361-8. View

4.
Simon D, Senan C, Balkau B, Saint-Paul M, Thibult N, Eschwege E . Reproducibility of HbA1c in a healthy adult population: the Telecom Study. Diabetes Care. 1999; 22(8):1361-3. DOI: 10.2337/diacare.22.8.1361. View

5.
Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P . Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia. 1999; 42(7):793-801. DOI: 10.1007/s001250051229. View